BioSpace News Archive

Tandem Diabetes Care, Inc. (NASDAQ: TNDM), a leading insulin delivery and diabetes technology company, plans to release its first quarter 2023 results after the financial markets close on Wednesday, May 3, 2023.

Longboard Pharmaceuticals, Inc. (Nasdaq: LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today announced that Brandi Roberts, Longboard’s Chief Financial Officer, will present at the 22nd Annual Needham Virtual Healthcare Conference on Tuesday, April 18, 2023, at 4:30pm ET.

Avation Medical, Inc., the innovator in patient-friendly, closed-loop neuromodulation options to treat life-altering medical conditions, today announced that its Vivally System received US Food and Drug Administration (FDA) 510(k) clearance.

RegeneRx Biopharmaceuticals, Inc., a clinical-stage drug development company focused on tissue protection, repair, and regeneration, has issued a Letter to Stockholders updating its ongoing operating strategy.

HUTCHMED Limited announces that new and updated clinical and non-clinical data related to five HUTCHMED investigational drug candidates will be presented during the American Association for Cancer Research Annual Meeting 2023, which will take place from April 14 to 19, 2023 in Orlando, Florida.

InflaRx N.V., a clinical-stage biopharmaceutical company developing anti-inflammatory therapeutics by targeting the complement system, announced the pricing of its underwritten public offering of 9,411,765 ordinary shares at an offering price of $4.25 per ordinary share.

Takeda Receives FDA Approval to Expand the Use of HYQVIA ® to Treat Primary Immunodeficiency in Children.

AtriCure, Inc. today announced that it will release first quarter 2023 financial results on Tuesday, May 2, 2023.

Ray Therapeutics announced today that Peter Francis, M.D., Ph.D., Chief Scientific and Medical Officer, will present at two upcoming scientific conferences: the 2023 Cell & Gene Meeting on the Med and the Eighth Annual Retinal Cell and Gene Therapy Innovation Summit (held during the 2023 ARVO Annual Meeting).

Halberd Corporation (OTC PINK:HALB) has announced that preclinical testing is now underway at Mississippi State University (MSU) for its groundbreaking patent-pending nasal spray designed to suppress the negative effects of Traumatic Brain Injury (TBI).